< Zurück zu den aktuellen Neuigkeiten & Events

Neuigkeiten

Notice from the European Patent Office dated 22 February 2021 concerning the amendment of Rules 19 and 143 EPC

März 2021

From 1 April 2021, inventors will no longer be notified by the EPO about being named in a patent application. In addition, applicants will no longer be required to indicate the full address of the inventor in the application, only the country and place of residence.

Amended Rule 19 (comes into force 1 April 2021):
  • Inventors are no longer notified by the EPO about their designation.
  • Applicants are no longer required to indicate the full address of the inventor only the country, city and post code.
  • Online filing tools will be updated so that they no longer have a dedicated field for entering a full address; nor will there be a dedicated field for „Company“ or „Department“ for inventors.
Amended Rule 143 (comes into force 1 Nov 2021):
  • Full addresses of inventors are no longer published in the EP patent register – only the country and place of residence.

Rule 20(1) still holds and is unaffected by either amended Rule 19 or Rule 143. An inventor can therefore still waive their right to be mentioned.

Reasons for the Changes:

Read the article here.

The EPO sends letters to notify inventors that they have been named on an application which is a considerable administrative burden (530,194 letters were sent in 2019 costing 307,000 EUR). In addition many of these letters are undeliverable due to incorrect addresses (36,000 in total). Updating online filing tools on the EPO IT systems will cost 50,000 EUR initially but save money in the long run.

Furthermore, due to data protection the EPO feel it is unnecessary to have the whole of the inventor’s address published on the EP patent register and that the name and city of the inventor is sufficient.

If you would like further advice on this or any other matter, please contact your usual HGF attorney or visit our Contact Page to get in touch with your nearest HGF office.

Aktuelle Neuigkeiten

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Weiterlesen

PRESSEMITTEILUNG HGF stärkt seine Präsenz in Europa mit drei neuen Partnern in Frankreich und Deutschland

HGF stärkt seine Präsenz in Europa mit drei neuen Partnern in Frankreich und Deutschland HGF freut sich, die Aufnahme von drei neuen Partnern bekannt zu geben, die die Präsenz des …

Weiterlesen

Quinas Technology Wins WIPO Global Award for Innovation in ICT

Our client, Quinas Technology, has been named the winner of the WIPO Global Award 2025 in the ICT Startup category. Quinas is a spin-out from Lancaster University. We have worked …

Weiterlesen

G1/23: The Enlarged Board of Appeal shift EPO practice towards an “on-sale” bar.

Last week, the EPO’s Enlarged Board of Appeal (EBA) issued its Decision that both a product put on the market before the date of filing of a European patent application, …

Weiterlesen

Briefing Note: UKIPO SEP Consultation

Overview and Strategic Context The UKIPO’s 2025 consultation on Standard Essential Patents (SEPs), announced on 15 July 2025, signals a potential policy shift in how the UK approaches SEP licensing …

Weiterlesen

HGF recognised in Managing IP’s New “Trusted Talent” Table in Germany

We are proud to announce that HGF has been ranked in Managing IP’s newly launched Trusted Talent table in Germany, a recognition of our ongoing commitment to excellence in intellectual …

Weiterlesen

ICELAND left out in the cold by the General Court

Earlier in the month, the EU General Court issued its decision on Iceland Foods Ltd’s appeal of a decision of the Grand Board of Appeal of EUIPO to invalidate an …

Weiterlesen

A leading case - beware sequence errors in patent claims

Samsung Bioepis UK Ltd v Alexion Pharmaceuticals Inc [2025] EWHC 1240 (Pat) – Mr Justice Meade – 20 May 2025 The UK Patents Court has held that Samsung Bioepis’ and Amgen’s …

Weiterlesen